Needham Upgrades Rocket Pharmaceuticals to Buy, Announces $9 Price Target
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsUpgradesPrice Target
Needham analyst Gil Blum upgrades Rocket Pharmaceuticals (NASDAQ:RCKT) from Hold to Buy and announces $9 price target.
Needham analyst Gil Blum upgrades Rocket Pharmaceuticals (NASDAQ:RCKT) from Hold to Buy and announces $9 price target.